Age, Sex, and Valve Phenotype Differences in Fibro-Calcific Remodeling of Calcified Aortic Valve

Martine Voisine, BSc*; Maxime Hervault, MSc*; Mylène Shen, MSc*; Anne-Julie Boliard, BSc; Benoît Filion, PhD; Mickael Rosa, PhD; Yohan Bossé, PhD; Patrick Mathieu, MD, MSc; Nancy Côté, PhD; Marie-Annick Clavel, DVM, PhD

BACKGROUND: In calcific aortic valve disease on tricuspid aortic valves (TAVs), men have higher aortic valve calcification and less fibrosis than women. However, little is known in bicuspid aortic valves (BAV). We thus aimed to investigate the impact of age, sex, and valve phenotype (TAVs versus BAVs) on fibro-calcific remodeling in calcific aortic valve disease.

METHODS AND RESULTS: We included 2 cohorts: 411 patients who underwent multidetector computed tomography (37% women) for aortic valve calcification density assessment and 138 explanted aortic valves (histological cohort; 50% women). The cohorts were divided in younger (<60 years old) or older patients with BAV (≥60 years old), and TAV patients. In each group, women and men were matched. Women presented less aortic valve calcification density than men in each group of the multidetector computed tomography cohort (all P≤0.01). Moreover, in women, younger patients with BAV had the lowest aortic valve calcification density (both P=0.02). In multivariate analysis, aortic valve calcification density correlated with age (β estimate±standard error: 6.5±1.8; P=0.0004) and male sex (109.2±18.4; P<0.0001), and there was a trend with TAVs (41.5±23.0; P=0.07). Women presented a higher collagen content than men (77.8±10.8 versus 69.9±12.9%; P<0.001) in the entire cohort. In women, younger patients with BAV had denser connective tissue than TAV and older patients with BAV (both P<0.05), while no difference was observed between men.

CONCLUSIONS: In calcific aortic valve disease, women had less calcification and more fibrotic remodeling than men, regardless of the phenotype of the valve or age of the patient. Moreover, younger women with BAVs had less valve calcification. Thus, mineralization/fibrosis of the aortic valve is likely to have sex/age-specific mechanisms and be influenced by the valve morphology.

Key Words: aortic stenosis — bicuspid — calcification — fibrosis — sex — tricuspid

Calcific aortic valve disease (CAVD) is the most frequent valvular heart disease in high-income countries and the second most common indication for cardiac surgery after coronary artery bypass grafting.1 CAVD is characterized by a complex pathophysiology, which involves a fibro-calcific remodeling of the leaflets.2 The incidence of CAVD increases markedly with age and affects 3% of the population over 65 years of age and 4.6% of the population over 75 years old.3,4 Male sex has been associated with a 2-fold increased risk to develop CAVD.5,6 Bicuspid aortic valve (BAV) is the most frequent cardiac congenital abnormality affecting 1% to 2% of the general population, with a ratio of 3 men to 1 woman.7 BAV is characterized by an aortic valve presenting 2 leaflets instead of 3. CAVD is the most common complication of BAV and develops 10 to 15 years earlier in BAV compared with patients with tricuspid aortic valve...
Voisine et al Age and Sex Differences in Calcified Aortic Valves

**CLINICAL PERSPECTIVE**

**What Is New?**
- Hemodynamic severity of aortic stenosis may not be correlated to the degree of aortic valve calcification in young women with bicuspid aortic valve; that is, young women may have a hemodynamically severe aortic stenosis with no or minimal aortic valve calcification.
- Women have a more fibrotic remodeling of the aortic valve, while men have a more calcific remodeling, irrespective of valve phenotype or age of the patients.

**What Are the Clinical Implications?**
- Quantification of aortic valve calcification should thus be interpreted with caution in young women with bicuspid aortic valve.
- The calcific/fibrotic patterns will be important to understand to develop pharmaceutical therapies, and especially to design studies to test these therapies.
- In women, the menopausal status may need to be taken into consideration to individualize strategy.

**Nonstandard Abbreviations and Acronyms**

| Abbreviation | Description |
|--------------|-------------|
| AVAi         | indexed aortic valve area |
| AVC          | aortic valve calcification |
| BAV          | bicuspid aortic valve |
| CAVD         | calcific aortic valve disease |
| MDCT         | multidetector computed tomography |
| MG           | mean transvalvular gradient |
| OBAV         | older patients with bicuspid aortic valve |
| TAV          | tricuspid aortic valve |
| YBAV         | younger patients with bicuspid aortic valve |

(TAV). Patients with BAV are at higher risk for an aortic valve intervention during their lifetime, with nearly 50% of them needing an aortic valve replacement for CAVD.1,8

Mineralization and extensive valvular fibrosis are the 2 main culprit lesions of CAVD, leading to the thickening and stiffening of aortic valve leaflets and obstruction of cardiac outflow.9–11 Aortic valve calcification (AVC) load, measured by multidetector computed tomography (MDCT), and hemodynamic severity of aortic stenosis, assessed by Doppler echocardiography, are well correlated.12–14 We recently showed that AVC is a predictor of the severity of CAVD in patients with TAV independently of the age, whereas in patients with BAV a major interaction was found between AVC and age on determining the severity of the disease. Indeed, AVC was a predictor of stenosis severity in older BAV but not in younger patients with BAV.15

Moreover, women reach similar hemodynamic stenosis severity than men for a lower AVC load.16,17 We have previously shown in TAV that this sex-related discrepancy was linked to higher valvular fibrosis in women compared with men.16 Whether these results are observed in patients with BAV have not been investigated yet. However, such differences in calcification/fibrosis ratio in men versus women, TAV versus BAV, and younger versus older patients could be of major importance to better understand CAVD pathophysiology and, ultimately, develop medical therapies. Thus, the aim of this study was to determine sex-specific CAVD lesions according to age and aortic valve phenotype (TAV versus BAV).

**METHODS**

The authors declare that all supporting data and methods are available within the article.

**Patient Populations**

A total of 537 patients with CAVD who underwent a comprehensive Doppler transthoracic echocardiography and an MDCT (n=434; MDCT cohort) or an aortic valve replacement were recruited for the study. From the 537 selected patients, 138 surgically explanted aortic valves were collected from the Quebec Heart and Lung Institute’s tissue bank for histological studies (histological cohort). Patients with rheumatic aortic stenosis, infective endocarditis, cervical or thoracic radiotherapy-induced valve lesions, severe renal disease, reduced left ventricular ejection fraction (<50%), more than mild aortic/mitral regurgitation, mitral stenosis, or prior aortic valve procedure were excluded. Patients were classified into 3 groups according to age and valve phenotype: (1) younger patients with bicuspid aortic valve (YBAV, <60 years old); (2) older patients with bicuspid aortic valve (OBAV, ≥60 years old); and (3) patients with tricuspid aortic valves (TAVs). In each group, men and women were frequency (MDCT cohort) or 1:1 (histological cohort) matched for (in order of importance) age (within 3 years), hemodynamic severity of CAVD determined by peak aortic jet velocity (within 0.25 m/s) mean transvalvular gradient (MG; within 5 mm Hg), indexed aortic valve area (AVAi; 0.1 cm²/m²), stroke volume index (within 3 mL/m²), left ventricular ejection fraction (within 5%), estimated glomerular filtration rate, systolic blood pressure (within 5 mm Hg), body mass index (within 5 kg/m²; Figure 1).
The study protocol was approved by the research ethics committee of the Quebec Heart and Lung Institute, and the participants gave written informed consent.

**Clinical Data**

The clinical data included age, sex, body surface area, body mass index, documented diagnoses of hypertension, diabetes mellitus, coronary artery disease, renal disease, and estimated glomerular filtration rate, calculated using the formula of Modification of Diet in Renal Disease study.

**MDCT Scans and AVC Assessment**

MDCT scans without contrast were performed using a 64 slices helical scanner (Somatom Definition, Siemens AG Medical Solution, Germany) with a tube potential at 120 kV and a tube current-time product at 60 to 80 mAs. Operators blinded to patient data performed all MDCT examinations and analyses. The protocol for the MDCT image acquisition and interpretation was previously published. Image analyses were performed offline on dedicated workstations with validated software (Aquarius iNtuition, TeraRecon, Foster City, CA) for the measurement of AVC. AVC scores were quantified with the Agatston scoring method, and all AVC data were expressed in Agatston units. To account for smaller heart size in women, we calculated the AVC density by dividing the AVC score by the cross-sectional aortic annulus area ($\pi \times [\text{Aortic annulus diameter/2}]^2$) measured by echocardiography.

**Doppler Echocardiography**

Comprehensive Doppler echocardiography was performed using commercially available ultrasound system. All echocardiographic exams were performed by the same team of sonographers and cardiologists, and all images were analyzed in the same laboratory by experienced readers according to the current recommendations of the American Society of Echocardiography. Doppler echocardiographic indices of aortic stenosis severity included peak aortic jet velocity, MG obtained by the Bernoulli formula, and aortic valve area calculated by the continuity equation and indexed to body surface area (AVAi). Left ventricular systolic function was assessed using left ventricular ejection fraction as measured by the biplane Simpson method. Stroke volume was calculated by multiplying the left ventricular outflow tract area by the flow velocity-time integral obtained by pulsed wave Doppler and was indexed to body surface area.

**Aortic Valve Histology**

Each valve excised at the time of surgery was placed in a container filled with HEPES solution and analyzed in the department of pathology. One of the cusps was decalcified in Cal-Ex (Fisher, Nepean, Ontario, Canada) for 24 hours and fixed in formaldehyde 10% for histological processing. Aortic valve leaflets were embedded in optimal cutting temperature compound and 6 μm sections of the 138 matched YBAV, OBAV, and TAV men and women were obtained from a skilled
operator using a cryotome. Histological sections were analyzed with Masson’s trichrome and Picrosirius red staining. Masson’s trichrome staining allowed us to differentiate loose (light blue sections) and dense connective tissue (dark blue sections; Figure 2A). Picrosirius red staining was used to study, under polarized light, collagen fibers (red/orange/green; Figure 2B). All sections were fixed in acetone-methanol (60:40) at −20°C for 10 minutes and washed with running tap water for 5 minutes. All staining kits were obtained from Sigma-Aldrich Corporation (Ontario, Canada).

They were later analyzed with a homemade algorithm developed with MathWorks’s MATLAB software detecting pixel RGB values for color differentiation. Masson’s trichrome staining data were expressed as the ratio of dense and loose connective tissue area on the global tissue area in brightfield. Picrosirius red amount of collagen fibers were expressed as the ratio of polarized pixels on the global brightfield tissue pixels.

**Statistical Analysis**

Continuous variables were tested for normality by the Shapiro-Wilk test. Results were expressed as mean ±SD, median (percentile 25–75), or percentage as appropriate.

Differences between groups and sexes were evaluated by a 2-way ANOVA followed by Tukey post hoc tests for continuous normally distributed variables; Wilcoxon rank sum test, followed by Steel-Dwass post hoc tests for continuous non-normally distributed; and chi-square or Fisher exact tests as appropriate for categorical variables. In the MDCT cohort, correlates of AVC density were identified by univariate and multivariate linear regressions and presented with β estimate±standard error.

A $P<0.05$ was considered statistically significant. All statistical analyses were performed with JMP 14.0 (SAS Institute) and SigmaPlot 11.0 (Systat Software) softwares.

**Figure 2.** Masson’s trichrome and Picrosirius red staining of aortic valves according to the sex-age-phenotype group.

A. Valve histology at 20× original magnification with Masson’s trichrome staining. Dark blue sections represent collagen fibers (dense connective tissue); light blue sections represent extracellular matrix fibers (loose connective tissue); red and purple nodules represent calcium nodules; and red fibers represent myofibroblast-like cells. B. Valve histology at 20× under polarized light with Picrosirius red staining. Red-orange-green fibers represent collagen fibers. ♂ indicates men; ♀, women; OBAV, older patients with a bicuspid aortic valve; YBAV, younger patients with a bicuspid aortic valve; and TAV, tricuspid aortic valve. Scale bar=1 mm.
RESULTS

MDCT Cohort

Patients Characteristics

Among the 434 patients of the MDCT cohort, 310 (71%) patients had TAV (116 [37%] women, 76±7 years old), 55 (13%) were YBAV patients (14 [25%] women, 50±9 years old), and 69 (16%) were OBAV patients (22 [32%] women, 71±9 years old). Patient demographics and clinical characteristics are summarized in Table 1. The matched variables were not different between men and women in each group (all \( P \geq 0.25 \)). In each group, as expected, women had a lower body surface area and a lower prevalence of coronary artery disease. Given that YBAV patients were younger, they had fewer comorbidities than older TAV and OBAV patients. However, stenosis severity was comparable between sexes in the 3 groups (all \( P > 0.47 \)).

Differences in Aortic Valve Calcification Evaluated by MDCT

In YBAV, OBAV, and TAV groups, women had lower AVC density (YBAV: 202 [0–341] versus 476 [265–701] Agatston units/cm², \( P = 0.001 \); OBAV: 429 [227–929] versus 889 [477–1080] Agatston units/cm², \( P = 0.009 \) compared with men (Figure 3A). In women, YBAV patients had significantly lower AVC density than OBAV and TAV patients (both \( P = 0.02 \)). In men, OBAV patients presented a higher AVC density compared with YBAV and TAV patients (\( P = 0.003 \) and \( P = 0.0001 \), respectively), which may be related to a slightly more severe stenosis in OBAV patients (Figure 3B).

In univariate analysis, AVC density was correlated with stenosis severity (ie, AVAi and MG; all \( P \leq 0.0001 \)) in the whole cohort. After adjustment for body surface area, coronary artery disease, systolic blood pressure, diabetes mellitus, estimated glomerular filtration rate, stenosis severity (MG and AVAi), and stroke volume index, AVC density was significantly correlated to age (6.5±1.8; \( P = 0.0004 \)) and male sex (109.2±18.4; \( P < 0.0001 \)), and there was a trend toward association with tricuspid valve morphology (41.5±23.0; \( P = 0.07 \)). In univariate analysis, AVC density was correlated with stenosis severity (ie, AVAi and MG; all \( P \leq 0.0003 \)) in all groups, except in YBAV women (\( P = 0.45 \)). After adjusting for systolic blood pressure, coronary artery disease, estimated glomerular filtration rate, and stroke volume index, AVC density was correlated with stenosis severity (ie, AVAi and MG; all \( P < 0.004 \)) in all groups, except in OBAV women, where there was only a trend toward association (\( P = 0.06 \), and in YBAV women where the association was absent (both \( P \geq 0.58 \)). The interaction between phenotype and sex to predict AVC density was statistically significant (\( P = 0.02 \)).

Histological Cohort

Patients Characteristics

In the histological cohort, 76 patients were classified in the TAV (38 women, 72.4±8.1 years old), 22 in the YBAV group (11 women, 57.0±3.1 years old) and 40 in the OBAV group (20 women, 72.4±8.2 years old).

There were no significant differences between men and women inside each group except for body surface area (Table 2); ie, women had lower body surface area when compared with men in each group (all \( P < 0.001 \)). By design, YBAV patients were younger than OBAV and TAV patients (both \( P < 0.001 \)). As expected, they had a lower prevalence of systemic arterial hypertension when compared with TAV (\( P = 0.01 \)); however, they had a higher prevalence of coronary artery disease compared with OBAV.

Semiquantitative Assessment of Fibrous Tissue With Masson’s Trichrome and Picrosirius Staining

As previously shown,\(^6\) in our histological cohort, we confirmed by a semiquantification of Masson’s trichrome staining that women had a higher content of dense fibrosis compared with men (reaching statistical significance in the whole cohort, YBAV and TAV patients, all \( P < 0.05 \); Figure 5A). Interestingly, YBAV women seem to have more dense connective tissue than OBAV and TAV women (\( P = 0.05 \)). This difference in the amount of dense connective tissue was not seen in men (all \( P > 0.07 \)).

Picrosirius red staining showed that women had more collagen fibers than men in the entire cohort (77.8±10.8 versus 69.9±12.9%; \( P < 0.001 \)) and in TAV patients (77.7±8.4 versus 68.8±12.1%; \( P < 0.001 \), while there was only a trend in YBAV (78.0±15.7 versus 70.5±18.9%; \( P = 0.06 \)) and in OBAV (77.8±12.2 versus 71.6±10.8%; \( P = 0.09 \)) patients (Figure 5B). No difference was seen between groups nor interaction between sex and group (\( P = 0.79 \)). Interestingly, the percentage of collagen fibers was correlated with hemodynamic severity of the stenosis in YBAV women (\( P = 0.001 \)), while there was no significant association in other groups (all \( P > 0.14 \)).

DISCUSSION

Our study demonstrates for the first time that (1) women with stenosed BAV have less calcification than men for the same hemodynamic severity of CAVD and confirm that women with stenosed TAV have less calcification than men; (2) in young (<60 years of age)
### Table 1. Characteristics of the MDCT Cohort

|                        | YBAV (n=55) | OBAV (n=69) | TAV (n=310) | P Value for Interaction |
|------------------------|-------------|-------------|-------------|-------------------------|
|                        | Men (n=41)  | Women (n=14)| Men (n=47)  | Women (n=22)            |                          |
| Clinical data          |             |             |             |                         |                          |
| Age, y                 | 50.3±7.8    | 47.2±11.3   | 70.3±6.6    | 73.4±7.2                | 0.67                     | 75.4±8.3                 | 76.9±9.1                 | 0.66                     | <0.001*†‡               |
| Body mass index, kg/m² | 29.5±4.9    | 27.4±7.6    | 27.4±3.8    | 26.1±3.9                | 0.90                     | 27.4±4.1                 | 28.3±6.4                 | 0.55                     | 0.06                     |
| Body surface area, m²  | 2.08±0.15   | 1.72±0.19   | 1.98±0.15   | 1.61±0.14               | <0.001†                  | 1.94±0.17                | 1.70±0.18                | <0.001§                  | <0.001*†                 |
| Systolic blood pressure, mm Hg | 124±14 | 118±13 | 127±21 | 128±17 | 1.00 | 131±18 | 133±19 | 0.82 | 0.006† |
| Diastolic blood pressure, mm Hg | 77±8 | 73±9 | 73±9 | 71±9 | 0.98 | 70±10 | 70±11 | 1.00 | 0.004† |
| eGFR, mL/min           | 77.3±17.9   | 77.4±19.2   | 66.9±16.8   | 61.2±14.7               | 0.88                     | 63.2±16.5                | 59.9±19.8                | 0.76                     | <0.001†                 |
| Coronary artery disease, n (%) | 10 (25) | 0 (0) | 16 (34) | 5 (23) | 0.43  | 101 (52) | 37 (32) | 0.001* | <0.001†‡ |
| Diabetes mellitus, n (%) | 8 (20) | 1 (7) | 7 (15) | 3 (14) | 0.92 | 55 (28) | 25 (22) | 0.23 | 0.16   |
| Hypertension, n (%)    | 18 (44)     | 4 (29)      | 28 (59)     | 13 (59)                 | 0.97                     | 144 (74)                 | 88 (76)                  | 0.81                     | <0.001*†‡               |
| Doppler echocardiographic data |     |             |             |                         |                          |                          |                          |                          |                          |
| Peak aortic jet velocity, m/s | 3.94±0.89 | 3.79±0.84 | 4.27±0.70 | 4.25±0.98 | 1.00 | 3.64±0.73 | 3.75±0.87 | 0.87 | <0.001† |
| Mean gradient, mm Hg   | 39±18       | 34±15       | 45±16       | 48±24                   | 0.98                     | 32±14                    | 35±16                    | 0.78                     | <0.001† |
| Aortic valve area index, cm²/m² | 0.54±0.15 | 0.56±0.16 | 0.48±0.12 | 0.45±0.18 | 0.94 | 0.58±0.11 | 0.59±0.13 | 1.00 | <0.001† |
| Stroke volume index, mL/m² | 45±10     | 44±7        | 44±9        | 40±8                    | 0.47                     | 44±9                     | 45±8                     | 0.97                     | 0.45                     |
| Left ventricular ejection fraction, % | 63±5      | 65±4        | 63±6        | 63±7                    | 1.00                     | 64±6                     | 66±6                     | 0.19                     | 0.02†                     |

eGFR indicates estimated glomerular filtration rate; OBAV, older patients with a bicuspid aortic valve; TAV, patients with a tricuspid aortic valve; and YBAV, younger patients with a bicuspid aortic valve.

*P<0.05 for YBAV vs OBAV; †P<0.05 for YBAV vs TAV; ‡P<0.05 for OBAV vs TAV.
women with BAV, the degree of aortic valve calcification is not related to hemodynamic severity of aortic stenosis, while the quantity of dense connective tissue is; (3) the quantity of dense connective tissue was higher in young BAV women than in other female groups. Interestingly, this variation of dense connective tissue was not seen in men according to phenotype of the valve and age; and (4) collagen fibers are more abundant in women than in men but without differences between the valve morphology (BAV versus TAV) or the age of the patients.

Several studies have recently shown that women, for similar aortic stenosis severity, exhibit lower AVC than men after taking into account the effect of smaller body size, heart, and aortic annulus size. Apart from genetic mutations related to BAV and CAVD development, mechanical stress has been pointed out as an important feature leading to calcification and fibrosis of bileaflet valves. Interestingly, electron microscopy established that the ventricular side of the BAV is massively stripped from the protective endothelium layer compared with TAV, suggesting a much higher mechanical stress imposed on BAVs. In our study, the level of calcification was indeed higher in younger and older men with BAVs compared with men with TAVs, supporting these results. However, the degree of fibrosis was not affected by the morphology of the valve in all the different age groups in men, but was higher in women with TAVs. In the literature, numerous in vitro studies using Flexcell technology to reproduce the different forces imposed on valvular interstitial cells have been published. Proteins implicated in the development of the valvular mineralization (ie, bone morphogenetic protein 2, osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, osteocalcin, osteopontin) have been highlighted as well as many markers of fibrosis and extracellular matrix reorganization like matrix metalloproteinases. Unfortunately, none of these studies investigated the sexual differences in response to these stimuli. However, one could speculate that, as
we obtained in our study, the calcification markers are upregulated in men with BAVs as well as TAVs but to a lesser extent, while in women, actors of the fibrotic processes could be activated independently of valvular morphology and age of the patients, and result in enhanced remodeling.

Sex hormones may also have an impact on valve calcification. Recently, androgen receptors have been found to be expressed in aortic valves and their expression was more important in calcified valves.33 In this study, in vitro testosterone supplementation increased calcification of vascular smooth muscle cells, while in other studies the opposite was found.34 In postmenopausal women, PvuII polymorphism in estrogen receptor α gene is related to the development of CAVD.35 Also, β-estradiol treatment of rat/porcine valvular interstitial cells cultured in osteogenic media decreased cell proliferation in female cells.36 However, the used osteogenic media contained a high concentration of dexamethasone, which may have an antiestrogen effect. In women, the calcification process seemed to be influenced by the phenotype of the valve and, more importantly, by the age of the patient, while fibrosis is not regulated by these factors. Especially in young BAV women, calcification is less important, while collagen content is equivalent to that of older BAV and TAV patients, and connective tissue appears to be more dense. These age-related differences were not seen in men. This could be linked to the hormonal status that is different in women before and after menopause.

Finally, response to other stimuli could be differently regulated in men and women, such as the higher impact of interferon-α in men compared with women. Interferon-α is a weak proinflammatory cytokine that cooperates with lipopolysaccharide in aortic valve interstitial cells. In cell culture, inflammation, apoptosis, and osteoblastic differentiation were more important after 24 hours of a treatment with interferon-α in men.
### Table 2. Characteristics of the Histological Study Population

| Clinical data                     | YBAV (n=22) | OBAV (n=40) | TAV (n=76) | P Value for Interaction |
|-----------------------------------|-------------|-------------|------------|-------------------------|
| Age, y                            | 56.5±3.6    | 57.5±2.5    | 69.1±6.2   | 69.5±5.5    | 0.80 | 72.7±7.6   | 72.2±8.8   | 0.65 | 0.75 ^† |
| Body mass index, kg/m²            | 28.7±6.2    | 27.1±4.1    | 28.0±4.1   | 27.0±3.4    | 0.05 | 29.2±5.3   | 30.6±6.4   | 0.19 | 0.18 |
| Body surface area, m²             | 1.98±0.2    | 1.70±0.13   | <0.001     | 1.93±0.19   | 1.70±0.16  | <0.001     | 1.97±0.21  | 1.81±0.21  | <0.001   | 0.26 |
| Systolic blood pressure, mm Hg    | 118±13      | 128±18      | 0.14       | 130±14      | 130±11    | 0.37       | 128±17     | 135±17    | 0.61     | 0.72 |
| Diastolic blood pressure, mm Hg   | 76±9        | 76±12       | 0.92       | 79±9        | 77±7      | 0.40       | 71±9       | 74±11     | 0.75     | 0.33 |
| eGFR, mL/min                      | 83.7±13.1   | 82.2±17.3   | 0.87       | 79.3±14.4   | 79.1±15.1 | 0.83       | 80.6±20.5  | 76.8±17.1 | 0.27     | 0.75 |
| Coronary artery disease, n (%)    | 5 (45)      | 4 (36)      | 0.66       | 2 (10)      | 3 (15)    | 0.63       | 24 (63)    | 20 (53)   | 0.35     | <0.001^‡ |
| Diabetes mellitus, n (%)          | 4 (36)      | 1 (9)       | 0.13       | 6 (30)      | 4 (16)    | 0.46       | 14 (37)    | 15 (39)   | 0.81     | 0.29 |
| Hypertension, n (%)               | 7 (63)      | 7 (63)      | 1.00       | 17 (85)     | 16 (80)   | 0.67       | 32 (84)    | 35 (92)   | 0.15     | 0.09^† |
| Echocardiographic data            |             |             |            |             |            |            |            |            |            |
| Peak aortic jet velocity, m/s     | 4.24±0.45   | 4.31±0.56   | 0.89       | 3.67±0.99   | 3.78±0.80  | 0.19       | 3.83±0.75  | 3.78±0.81  | 0.65     | 0.42 |
| Mean gradient, mm Hg              | 45±10       | 45±9        | 0.84       | 45±13       | 45±15     | 0.86       | 40±14      | 39±12     | 0.28     | 0.73 |
| Aortic valve area index, cm²/m²   | 0.41±0.05   | 0.39±0.09   | 0.43       | 0.38±0.09   | 0.38±0.08  | 0.99       | 0.41±0.07  | 0.40±0.09  | 0.97     | 0.81 |
| Stroke volume index, mL/m²        | 41±7        | 41±8        | 0.98       | 41±13       | 39±9      | 0.44       | 39±6       | 40±8      | 0.17     | 0.21 |
| Left ventricular ejection fraction, % | 63±6       | 62±9        | 0.57       | 61±4        | 63±5      | 0.36       | 60±8       | 61±7      | 0.51     | 0.59 |

eGFR indicates estimated glomerular filtration rate; OBAV, older patients with a bicuspid aortic valve; TAV, patients with a tricuspid aortic valve; and YBAV, younger patients with a bicuspid aortic valve.

^P<0.05 for YBAV vs OBAV; †P<0.05 for YBAV vs TAV; ‡P<0.05 for OBAV vs TAV.
compared with women, which may explain the increase in aortic valve calcification in men compared with women.

A recent study investigated the sex differences in the pathology of aortic valves in rheumatic heart disease, an autoimmune disease caused by group A streptococci infection and frequently affecting the aortic valve. Aortic valves from female patients had increased collagen, monocytes/macrophages, neovascularization, and inflammatory genes involved in the nuclear factor kappa-light-chain enhancer of activated B cells pathway. They also found reduced apoptotic signals in women, which is consistent with reduced mineralization that we observed in our specimens from female patients.

Interestingly, it seems like the disease is more similar between OBAV and TAV than in YBAV patients. These findings suggest that the pathophysiological mechanisms leading to the development of CAVD might be, at least in part, different between the older and the younger middle-aged patients. In the younger patients, it is believed that lipid-mediated inflammation, and insulin resistance might play a predominant role in the pathogenesis of CAVD, whereas altered phosphocalcic metabolism and activation of the renin-angiotensin system might be the cause in older patients. Further studies are needed to identify the age-related differences in the pathogenesis of CAVD.

However, sex-specific pathophysiology of CAVD explaining the differences observed between men and women and in women between YBAV, OBAV, and TAV patients are far from being understood. The understanding of these processes may help develop targeted medical therapies in aortic stenosis.

**LIMITATIONS**

The principal limitation of this study is the limited number of stenosed BAVs. The smaller BAV group translates into lower power to detect differences.

**CONCLUSIONS**

In stenosed aortic valves, the pathophysiology appears to be sex-specific and probably age-specific in women. Aortic valves explanted from women present with less calcification and denser connective tissue, with more fibrosis than men regardless of age and phenotype (i.e., bicuspid versus tricuspid). Moreover, YBAV women had the lowest valve calcification for the same hemodynamic stenosis severity compared with...
OBAV and TAV women. This age-related difference was not seen in men. Further studies are required to better understand aortic valve remodeling in aortic stenosis according to the sex and age of the patient.

ARTICLE INFORMATION
Received January 30, 2020; accepted April 7, 2020.

Affiliations
From the Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart and Lung Institute, Université Laval, Québec City, Québec, Canada.

Acknowledgments
We thank Véronique Tremblay, Geneviève Guévremont, Marie-Chloé Boulanger, and the IUCPQ Biobank (Christine Racine and Caroline Gagnon) for their valuable collection and their technical assistance.

Sources of Funding
This study was funded by the Heart and Stroke Foundation of Canada (Grant-in-aid #G-18-002213).

Disclosures
None.

REFERENCES
1. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. *Circulation.* 2005;111:920–925.

2. Lindman BR, Clavel MA, Mathieu P, Iung B, Lancellotti P, Otto CM, Pibarot P. Calcific aortic stenosis. *Nat Rev Dis Primers.* 2016;2:e16006.

3. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. *Lancet.* 2006;368:1005–1011.

4. Carabello BA. Aortic stenosis. *N Engl J Med.* 2002;346:677–682.

5. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith 8. Braverman AC, Guven H, Beardslee MA, Makan M, Kates AM, Moon J, Malouf J, Aggarwal S, Clavel MA, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L, Mohr FW. Mechanical strain and the aortic valve: influence on fibroblast behavior. *Eur Heart J.* 2010;31:117–125.

6. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Spertus JA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. *Circulation.* 2017;135:2001–2091.

7. Voisine et al. Age and Sex Differences in Calcified Aortic Valves. *J Am Coll Cardiol.* 2013;62:2539–2548.

8. Braverman AC, Guven H, Beardslee MA, Makan M, Kates AM, Moon J, Malouf J, Aggarwal S, Clavel MA, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L, Mohr FW. Mechanical strain and the aortic valve: influence on fibroblast behavior. *Eur Heart J.* 2010;31:117–125.

9. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Spertus JA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. *Circulation.* 2013;128:2539–2548.

10. Mohr ER, Sherridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: atherosclerosis risk factors—a causal relationship? A clinical morphologic study. *Clin Cardiol.* 1991;14:995–999.

11. Siu SC, Silversides CK. Bicuspid aortic valve disease. *J Am Coll Cardiol.* 2010;55:2789–2800.

12. Braverman AC, Guven H, Beardslee MA, Makan M, Kates AM, Moon MR. The bicuspid aortic valve. *Curr Probl Cardiol.* 2005;30:470–522.

13. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol.* 1990;15:927–932.

14. Baumgartner H, Jung J, Bermejo J, Chambers JB, Evangelista A, Griffith BP, Iung B, Otto CM, Pibarot PA, Quinones M. Echocardiographic assessment of valve stenosis: EAE/EAS recommendations for clinical practice. *J Am Soc Echocardiogr.* 2009;22:1–23.

15. Voisine et al. Age and Sex Differences in Calcified Aortic Valves. *J Am Coll Cardiol.* 2013;62:2539–2548.

16. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Spertus JA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. *Circulation.* 2017;135:2001–2091.

17. Voisine et al. Age and Sex Differences in Calcified Aortic Valves. *J Am Coll Cardiol.* 2013;62:2539–2548.

18. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Spertus JA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. *Circulation.* 2017;135:2001–2091.

19. Voisine et al. Age and Sex Differences in Calcified Aortic Valves. *J Am Coll Cardiol.* 2013;62:2539–2548.

20. Baumgartner H, Jung J, Bermejo J, Chambers JB, Evangelista A, Griffith BP, Iung B, Otto CM, Pibarot PA, Quinones M. Echocardiographic assessment of valve stenosis: EAE/EAS recommendations for clinical practice. *J Am Soc Echocardiogr.* 2009;22:1–23.

21. Vahanian A, Iung B. The new ESC/EACTS guidelines on the management of valvular heart disease. *Arch Cardiovasc Dis.* 2012;105:465–477.

22. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Spertus JA, et al. 2017 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. *Circulation.* 2014;129:e521–e643.

23. Pawade T, Clavel MA, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L, Mohr FW. Mechanical strain and the aortic valve: influence on fibroblast behavior. *Eur Heart J.* 2011;32:162–169.

24. Dargis N, Lamontagne M, Gaudreault N, Sbarra L, Henry C, Pibarot P, Mathieu T, Bossey S. Identification of gender-specific genetic variants in patients with bicuspid aortic valve. *Am J Cardiol.* 2016;117:420–426.

25. Bochtchareh R, Boulanger M, Pepin A, Pibarot P, Mathieu P. Mechanical stress enhances aortic valve calcification: implication for bicuspid aortic valve mineralization. *Can J Cardiol.* 2012;28:S214; Abstract #317.

26. Bouchareb R, Boulanger M, Pépin A, Pibarot P, Mathieu P. Mechanical strain and progression of aortic valve stenosis: atherosclerosis risk factors—a causal relationship? A clinical morphologic study. *Clin Cardiol.* 1991;14:995–999.

27. Sui SC, Silversides CK. Bicuspid aortic valve disease. *J Am Coll Cardiol.* 2010;55:2789–2800.

28. Braverman AC, Guven H, Beardslee MA, Makan M, Kates AM, Moon MR. The bicuspid aortic valve. *Curr Probl Cardiol.* 2005;30:470–522.

29. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. *Circulation.* 1994;90:844–853.

30. Yetkin E, Waltenberger J. Molecular and cellular mechanisms of aortic stenosis. *J Int J Cardiol.* 2009;135:4–13.

31. Carabello BA. Aortic valve stenosis. *Lancet.* 2009;373:956–966.

32. Messika-Zeitoun D, Aubry MC, Detaint D, Bièлем AF, Peyser PA, Sheedy PF, Turner ST, Breen JF, Scott C, Tajik AJ, et al. Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography. *Circulation.* 2004;110:356–362.

33. Kaden JJ, Freyer S, Weissger G, Willingstorfer W, Bilbaj A, Plieger S, Susebeck T, Häaxe KK, Demple OE, Bœggrefre M. Correlation of degree of aortic valve stenosis by doppler echocardiogram to quantitation of calcium in the valve by electron beam tomography. *Am J Cardiol.* 2002;90:554–557.

34. Cuffe C, Serfaty J-M, Cimadevilla C, Laiswy JP, Himbert D, Tubach F, Duval X, Iung B, Enriquez-Sarano M, Vahanian A, et al. Measurement of aortic valve calcification using multislice computed tomography: correlation with haemodynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction. *Heart.* 2011;97:721–726.
35. Nordstrom P, Glader CA, Dahlen G, Birgander LS, Lorentzon R, Waldenstrom A, Lorentzon M. Oestrogen receptor alpha gene polymorphism is related to aortic valve sclerosis in postmenopausal women. *J Intern Med*. 2003;254:140–146.

36. Masjedi S, Lei Y, Patel J, Ferdous Z. Sex-related differences in matrix remodeling and early osteogenic markers in aortic valvular interstitial cells. *Heart Vessels*. 2017;32:217–228.

37. Parra-Izquierdo I, Castanos-Mollor I, Lopez J, Gomez C, San Roman JA, Sanchez Crespo M, Garcia-Rodriguez C. Calcification induced by type I interferon in human aortic valve interstitial cells is larger in males and blunted by a Janus kinase inhibitor. *Arterioscler Thromb Vasc Biol*. 2018;38:2148–2159.

38. Xiao F, Zheng R, Yang D, Cao K, Zhang S, Wu B, Shao Y, Zhou B. Sex-dependent aortic valve pathology in patients with rheumatic heart disease. *PLoS ONE*. 2017;12:e0180230.

39. Capoulade R, Clavel MA, Dumesnil JG, Chan KL, Teo JW, Côté N, Mathieu P, Pibarot P. Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. *J Am Coll Cardiol*. 2012;60:216–223.

40. Mohty D, Pibarot P, Després JP, Cartier A, Arsenault B, Picard F, Mathieu P. Age-related differences in the pathogenesis of calcific aortic stenosis: the potential role of resistin. *Int J Cardiol*. 2010;142:126–132.

41. Côté N, Couture C, Pibarot P, Després JP, Mathieu P. Angiotensin receptor blockers are associated with lower remodelling of stenotic aortic valves. *Eur J Clin Invest*. 2011;41:1172–1179.

42. Capoulade R, Clavel MA, Mathieu P, Côté N, Dumesnil JG, Arsenault M, Bédard E, Pibarot P. Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis. *Eur J Clin Invest*. 2013;43:1262–1272.

43. Côté N, Mahmoud A, Fournier D, Péguy A, Couture C, Després JP, Trahan S, Pagé S, Bossé Y, Pibarot P, et al. Angiotensin receptor blockers are associated with reduced fibrosis and interleukin-6 expression in calcific aortic valve disease. *Pathobiology*. 2014;81:15–24.